ファーマナビゲータ DIC編 改訂版
商品紹介
播種性血管内凝固（DIC）の薬理作用をはじめ、分類、病態と治療、処方の実際を解説。トピックス、Q&Aも掲載する。略語一覧、和文・欧文索引付き。メモ欄あり。
目次
- Chapter １ 薬理作用
１ 概念と最近の進展：DICとは（DICのメカニズム）
２ オンディマンド型反応系
Chapter ２ DICの分類
１ 時間経過に基づいた分類
２ 凝固と線溶のダイナミズムからみた分類
Chapter ３ 病態と治療
１ 病態基盤と病型
２ 診断基準
３ 治療総論（従来の治療と最新の治療）
４ DICと鑑別が必要な疾患 血栓性微小血管症（TMA）
５ DICと鑑別が必要な疾患 溶血性尿毒症症候群（HUS）
Chapter ４ 処方の実際
１ 造血器悪性腫瘍とDIC
２ 固形癌とDIC
３ 外科のDIC（リスクの高い手術）
４ 救急領域のDIC
５ 新生児領域のDIC
６ 産科・婦人科領域のDIC
７ DIC治療のEBM
Chapter ５ トピックス
１ PAMPs/DAMPs
２ 類洞閉塞症候群（SOS
３ ヘパリン起因性血小板減少症（HIT）
４ プロカルシトニン・プレセプシン
５ ADAMTS 13と血栓性血小板減少性紫斑病（TTP）
６ 特発性肺線維症（IPF）
７ 妊娠高血圧症候群
８ 抗リン脂質抗体症候群（APS）
９ 後天性フォンウィルブランド症候群（AVWS）
10 細胞外DNAと対外循環回路閉鎖
11 敗血症に伴うDIC
12 日本版敗血症診療ガイドライン
13 メディカルスタッフのDIC診療―看護師の立場から
14 メディカルスタッフのDIC診療―臨床検査技師の立場から
15 メディカルスタッフのDIC診療―薬剤師の立場から
Chapter ６ Question&Answer
１ いわゆる「線溶抑制型」DICと「線溶亢進型」DICでは，
DIC治療薬の使い分けが必要でしょうか
２ SIRSはDICを合併しやすいと聞きます。
SIRSという疾患概念について教えてください
３ 敗血症患者におけるDIC治療は，予後の改善をもたらしますか
４ 造血幹細胞移植に伴う合併症に対して，
抗凝固療法はどの程度期待できますか
５ DPCを念頭においた場合，DICの治療戦略はどうあるべきでしょうか
６ 小児に対するDIC治療薬の選択とそのエビデンスを教えてください
７ DICによって腎機能が障害された場合のDIC治療について，
どのような点に留意すればよいでしょうか
８ 急性期侵襲病態ではミトコンドリアはどのような役割をしているのでしょうか
９ アンチトロンビンと遺伝子組換え型トロンボモジュリンの使い分けに対する
考え方について教えてください
10 熱中症に伴うDICの治療について教えてください
この書籍の参考文献
参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。
本参考文献は電子書籍掲載内容を元にしております。
Chapter 1 薬理作用
P.32 掲載の参考文献
Chapter 2 DICの分類
P.46 掲載の参考文献
3) 和田英夫 : 播種性血管内凝固症候群 (DIC). 三輪血液病学 (浅野茂隆, 池田康夫, 内山卓監修). 文光堂, 東京, 2005, p 1743-1752
4) 青木延雄, 長谷川淳 : DIC診断基準の『診断のための補助的検査成績, 所見』の項の改訂について. 厚生省特定疾患血液凝固異常症調査研究班平成4年度業績報告集. 1988, p 37-41
5) Taylor FB Jr, Toh CH, Hoots WK et al : Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86 : 1327-1330, 2001
6) Gando S, Iba T, Eguchi Y et al : A multicenter, prospective validation of disseminated intra vascular coagulation diagnostic criteria for critically ill patients : comparing current criteria. Crit Care Med 34 : 625-631, 2006
7) Gando S, Wada H, Kim HK et al : Comparison of disseminated intravascular coagulation in trauma with coagulopathy of trauma/acute coagulopathy of trauma-shock. J Thromb Haemost 10 : 2593-2595, 2012
P.59 掲載の参考文献
1) 金沢大学血液内科・呼吸器内科 : 播種性血管内凝固症候群 (DIC). http://www.3nai.jp/weblog/entry/24539.html
3) Taylor FB Jr, Toh CH, Hoots WK et al : Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86 : 1327-1330, 2001
4) 日本血栓止血学会学術標準化委員会DIC部会 : 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス. 日血栓止血会誌 20 : 77-113, 2009
5) 林朋恵, 朝倉英策 : 播種性血管内凝固症候群の病態・診断. わかりやすい血栓と止血の臨床 (日本血栓止血学会編). 南江堂, 東京, 2011, p 190-194
8) 朝倉英策 : トラネキサム酸 (トランサミン). 臨床に直結する血栓止血学 改訂2版 (朝倉英策編). 中外医学社, 東京, 2018, p 671-676
9) 朝倉英策 : 播種性血管内凝固症候群 (DIC). しみじみ分かる血栓止血vol. 1 DIC・血液凝固検査編. 中外医学社, 東京, 2014, p 48-141
Chapter 3 病態と治療
P.69 掲載の参考文献
1) 朝倉英策 : 播種性血管内凝固症候群 (DIC). 臨床に直結する血栓止血学 (朝倉英策編). 中外医学社, 東京, 2013, p 168-178
2) Matthay MA : Severe sepsis-a new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med 344 : 759-762, 2001
4) Brown JE, Olujohungbe A, Chang J et al : All-trans retinoic acid (ATRA) and tranexamic acid : a potentially fatal combination in acute promyelocytic leukaemia. Br J Haematol 110 : 1010-1012, 2000
5) Pogliani EM, Rossini F, Casaroli I et al : Thrombotic complications in acute promyelocytic leukemia during all-trans-retinoic acid therapy. Acta Haematol 97 : 228-230, 1997
7) Hashimoto S, Koike T, Tatewaki W et al : Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. Leukemia 8 : 1113-1115, 1994
9) Kocak U, Gursel T, Ozturk G, Kantarci S : Thrombosis during all-trans-retinoic acid therapy in a child with acute promyelocytic leukemia and factor VQ 506 mutation. Pediatr Hematol Oncol 17 : 177-180, 2000
18) Nakamura D, Yoshimitsu M, Kawada H et al : Recombinant human soluble thrombomodulin for the treatment of hepatic sinusoidal obstructive syndrome post allogeneic hematopoietic SCT. Bone Marrow Transplant 47 : 463-464, 2012
P.80 掲載の参考文献
3) 中川雅夫 : 厚生省特定疾患血液系疾患調査研究班, 血液凝固異常症分科会, 平成10年度研究業績報告書. 1999, p 57-72
4) Taylor Jr FB, Toh CH, Hoots WK et al : Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation-On behalf of the Scientific Subcommittee on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Thromb Haemost 86 : 1327-1330, 2001
5) 青木延雄, 長谷川淳 : DIC診断基準の『診断のための補助的検査成績, 所見』の項の改訂について. 厚生省特定疾患血液凝固異常症調査研究班, 平成4年度業績報告集, 1988, p 37-41
6) 松田保 : DICの臨床-播種性血管内凝固の臨床-. 新興医学出版, 東京, 1997, p 1
9) Gando S, Iba T, Eguchi Y et al : Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group : A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients : comparing current criteria. Crit Care Med 34 : 625-631, 2006
10) Colman RW, Robby SJ, Minna JD : Disseminated intravascular coagulation (DIC) : an approach. Am J Med 52 : 679-689, 1972
11) Al-Mondhiry H : Disseminated intravascular coagulation : experience in a major cancer center. Thromb Diath Haemorrh 34 : 181-193, 1975
12) 松田保 : 播種性血管内凝固 (DIC). 臨床血液 17 : 1139-1152, 1976
13) Siegal T, Seligsohn U, Aghai E et al : Clinical and laboratory aspects of disseminated intravascular coagulation (DIC) : a study of 118 cases. Thromb Haemosts 39 : 122-134, 1978
14) Spero JA, Lewis JH, Hasiba U : Disseminated intravascular coagulation. Findings in 346 patients. Thromb Haemosts 43 : 28-33, 1980
15) 松田保, 朝倉英策, 山崎雅英ほか : DIC診断基準の問題点 : フィブリノゲンとプロトロンビン時間の問題点について. 厚生省特定疾患血液凝固異常症調査研究班, 平成4年度業績報告集, 1993, p 24-30
16) Toh CH, Downey C : Performance and prognostic importance of a new clinical and laboratory scoring system for identifying non-overt disseminated intravascular coagulation. Blood Coagul Fibrinolysis 16 : 69-74, 2005
18) Egi M, Morimatsu H, Wiedermann CJ et al : Non-overt disseminated intravascular coagulation scoring for critically ill patients : The impact of antithrombin levels. Thromb Haemost 101 : 696-705, 2009
P.92 掲載の参考文献
2) Warren BL, Eid A, Singer P et al : High-dose antithrombin in severe sepsis. A randomized controlled trial. JAMA 286 : 1869-1878, 2001
4) Aoki N, Matsuda T, Saito H et al : A comparative double blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. Int J Hematol 75 : 540-547, 2002
9) Di Nisio M, Baudo F, Cosmi B et al : on behalf of the Italian Society for Thrombosis and Haemostasis. Diagnosis and treatment of disseminated intravascular coagulation : Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res 129 : e177-e184, 2012
10) Wada H, Thachil J, Di Nisio M et al : Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines. J Thromb Haemost 11 : 761-767, 2013
11) 西田修, 小倉裕司, 井上茂亮ほか : 日本版敗血症診療ガイドライン 2016, 日救急医会誌 28 : S5-S12, 2017
12) 神前五郎, 神林純一, 平山亮夫ほか : DICに対するFOYの治療効果に関する研究-多施設比較臨床試験-. 医学のあゆみ 124 : 144-154, 1983
13) 柴田昭, 高橋芳右, 服部晃ほか : DICに対するFUT-175注の治療効果-多施設比較臨床試験による検討- 臨床と研究 65 : 921-940, 1988
16) Wada H, Matsumoto T, Yamashita Y et al : Is early treatment of DIC beneficial in septic patients? Crit Care 18 : 447, 2014
18) Hsu JT, Chen HM, Chiu DF et al : Efficacy of gabexate mesilate on disseminated intravascular coagulation as a complication of infection developing after abdominal surgery. J Formos Med Assoc 103 : 678-684, 2004
19) Kienast J, Juers M, Wiedermann CJ et al : Treatment effects of highdose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 4 : 90-97, 2005
23) Yamakawa K, Fujimi S, Mohri T et al : Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis : a historical control study. Crit Care 15 : R 123, 2011
25) Ranieri VM, Thompson BT, Barie PS et al : Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 366 : 2055-2064, 2014
P.103 掲載の参考文献
1) 非典型溶血性尿毒症症候群診断基準作成委員会 : 非典型溶血性尿毒症症候群 (aHUS) 診療ガイドライン 2015. https://cdn.jsn.or.jp/guideline/pdf/ahus_2016-2.pdf
2) 宮川義隆, 松本雅則, 南学正臣 : 血栓性微小血管症 (TMA) 診断・治療実践マニュアル. 東京, 医薬ジャーナル社, 2016
3) 日本造血細胞移植学会. 造血細胞移植ガイドラインSOS/TA-TMA. http://www.jshct.com/guideline/pdf/01_06_06_sos_ta-tma.pdf
4) Zeng L, Jia L, Xu S et al : Vascular endothelium changes after conditioning in hematopoietic stem cell transplantation : role of cyclophosphamide and busulfan. Transplant Proc 42 : 2720-2724, 2010
8) Carmona A, Diaz-Ricart M, Palomo M et al : Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells : protective effect of defibrotide. Biol Blood Marrow Transplant 19 : 1439-1445, 2013
10) Fujino M, Kim Y, Ito M : Intestinal thrombotic microangiopathy induced by FK 506 in rats. Bone Marrow Transplant 39 : 367-372, 2007
11) Bernardo A, Ball C, Nolasco L et al : Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 104 : 100-106, 2004
12) Seeber C, Hiller E, Holler E et al : Increased levels of tissue plasminogen activator (t-PA) and tissue plasminogen activator inhibitor (PAI) correlate with tumor necrosis factor alpha release in patients suffering from microangiopathy following allogeneic bone marrow transplantation (BMT). Thromb Res 66 : 373-383, 1992
13) Biedermann BC, Sahner S, Gregor M et al : Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 359 : 2078-2083, 2002
14) Nakamae H, Yamane T, Hasegawa T et al : Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. Am J Hematol 81 : 525-531, 2006
15) Fuchs TA, Brill A, Duerschmied D et al : Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 107 : 15880-15885, 2010
16) Xu J, Zhang X, Pelayo R et al : Extracellular histones are major mediators of death in sepsis. Nat Med 15 : 1318-1321, 2009
17) Arai Y, Yamashita K, Mizugishi K et al : Serum neutrophil extracellular trap levels predict thrombotic microangiopathy after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 19 : 1683-1689, 2013
18) Xia Z, Liu M, Wu Y et al. N-acetylcysteine attenuates TNF-alpha-induced human vascular endothelial cell apoptosis and restores eNOS expression. Eur J Pharmacol 550 : 134-142, 2006
19) Wang D, Wang Q, Yan G et al : High glucose and interleukin 1β-induced apoptosis in human umbilical vein endothelial cells involves in down-regulation of monocarboxylate transporter 4. Biochem Biophys Res Commun 466 : 607-614, 2015
20) Bernardo A, Ball C, Nolasco L et al : Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 104 : 100-106, 2004
21) Seeber C, Hiller E, Holler E et al : Increased levels of tissue plasminogen activator (t-PA) and tissue plasminogen activator inhibitor (PAI) correlate with tumor necrosis factor alpha (TNF alpha) -release in patients suffering from microangiopathy following bone marrow transplantation (BMT). Thromb Res 66 : 373-383, 1992
22) Jodele S, Davies SM, Lane A et al : Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy : a study in children and young adults. Blood. 124 : 645-653, 2014
23) Atefi G, Aisiku O, Shapiro N et al : Complement Activation in Trauma Patients Alters Platelet Function. Shock. 46 : 83-88, 2016
24) Mizuno T, Yoshioka K, Mizuno M et al : Complement component 5 promotes lethal thrombosis. Sci Rep 7 : 42714, 2017
25) 山下篤, 浅田祐士郎 : 血栓性微小血管症 (TMA) の最新の知見. 日本血栓止血学会誌 25 : 682-688, 2014
26) Ho VT, Cutler C, Carter S et al : Blood and marrow transplant clinical trials network toxicity committee consensus summary : thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11 : 571-575, 2005
P.117 掲載の参考文献
1) 香美祥二, 岡田浩一, 南学正臣ほか : 非典型溶血性尿毒症症候群 (aHUS) 診療ガイド117
3) 松本雅則 : 血栓性微小血管障害症 (TMA) -TTP, HUS, 移植後TMAを中心に. 医学のあゆみ 238 : 136-140, 2011
5) Bitzan M, Moebius E, Ludwig K et al : High incidence of serum antibodies to Escherichia coli O 157 lipopolysaccharide in children with hemolytic-uremic syndrome. J Pediatr 119 : 380-385, 1991
7) 五十嵐隆 : 溶血性尿毒症症候群の診断・治療ガイドライン. 東京, 東京医学社, 2014
9) Kidney Disease : Improving Global Outcomes Acute Kidney Injury Work Group ; Kidney International. suppl 2 : 2012, p 1-138
11) Hickey CA, Beattie TJ, Cowieson J et a : Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. JAMA 165 : 884-889, 2012
12) Honda T, Ogata S, Mineo E et al : A novel strategy for hemolytic uremic syndrome : successful treatment with thrombomodulin α. Pediatrics 131 : e928-e933, 2013
14) Shimizu M, Kuroda M, Sakashita N et al : Cytokine profiles of patients with enterohemorrhagic Escherichia coli O 111-induced hemolyticuremic syndrome. Cytokine 60 : 694-700, 2012
15) 佐多徹太郎 : 厚生労働省科学研究費補助金厚生労働省科学特別研究事業「EHEC/O 111 食中毒事例における疫学的・細菌学・臨床研究」平成23年度総括・分担研究報告書.
16) Tayler CM, Machin S, Wigmore SJ et al : Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 148 : 37-47, 2009
17) Ariceta G, Besbas N, Johnson S et al : Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 24 : 687-696, 2011
Chapter 4 処方の実際
P.125 掲載の参考文献
2) DIC診断基準作成委員会 : 日本血栓止血学会DIC診断基準 2017年版. 血栓止血誌 28 : 369-391, 2017
4) 一般社団法人日本血液学会編 : 造血器腫瘍診療ガイドライン 2018年版. 東京, 金原出版, 2018
P.132 掲載の参考文献
1) 中川雅夫 : 本邦における播種性血管内凝固 (DIC) の発症頻度・原因疾患に関する調査報告. 厚生省特定疾患・血液系疾患調査研究班血液凝固異常症分科会 平成10年度研究業績報告書, 1999, p 57-64
2) Weitz IC, Israel VK, Waisman JR et al : Chemotherapy-induced activation of hemostasis : effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. Thromb Haemost 88 : 213-220, 2002
3) 朝倉英策, 林朋恵, 前川実生ほか : DICの治療戦略. 日内会誌 98 : 1640-1647, 2009
5) 日本血栓止血学会学術標準化委員会DIC部会 : 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス. 日血栓止血会誌 20 : 77-113, 2009
P.139 掲載の参考文献
1) 丸藤哲, 池田寿昭, 石倉宏恭ほか : 急性期DIC診断基準. 第二次多施設共同前向き試験結果報告. 日救急医会誌 18 : 237-272, 2007
2) DIC診断基準作成委員会 : 日本血栓止血学会DIC診断基準 2017年版. 日血栓止血会誌 28 : 369-391, 2017
3) 丸山征郎, 坂田洋一, 和田英夫ほか : 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス. 日血栓止血会誌 20 : 77-113, 2009
P.144 掲載の参考文献
3) Hoffman M, Monroe III DM : A cell-based model of hemostasis. Thromb Haemost 85 : 958-965, 2001
P.155 掲載の参考文献
1) 白幡聡, 白川嘉継 : 新生児のDIC. 血栓止血誌 17 : 245-253, 2006
2) 椎木みどり, 有吉宣明, 中村外士雄, 白幡聡 : 新生児の凝固・線溶阻止因子の動態. 臨床血液 32 : 758-765, 1991
3) 下野昌幸, 浦野元, 高尾伸也ほか : 新生児期のプロテインCとプロテインSの動態-ビタミンK投与例での検討. 日本新生児誌 26 : 503-510, 1990
4) 白川嘉継, 中村外士雄, 白幡聡, 山岸稔 : 新生児期の血漿ヘパリンコファクター II値. 日本新生児誌 26 : 727-731, 1990
7) 丸山征郎 : DIC発現の新規メディエーターと臨床への応用を探る, DIC治療の新たなるストラテジー (丸藤哲編). 東京, 先端医学社, 2004, p 31-35
8) 岡島研二 : DICおよび重症感染症のアンチトロンビン III 濃縮製剤による治療. Biomed Perspect 2 : 75-82, 1993
9) 丸山征郎, 鈴木宏治 : 血管内皮細胞の抗血栓分子トロンボモジュリン (TM) による循環維持機構の解明と遺伝子組み換えTMによる血栓制御の臨床展開. 最新医学 64 : 264-289, 2009
P.165 掲載の参考文献
1) 小林隆夫 : 産科領域のDIC. 朝倉栄策編著, 臨床に直結する血栓止血学 改訂2版. 東京, 中外医学社, 2018, p 387-393
2) 小林隆夫 : 産科DIC. 日本産婦人科・新生児血液学会編集. 産婦人科・新生児領域の血液疾患診療の手引き. 東京, メジカルビュー社, 2017, p 97-108
3) 小林隆夫 : 産科DICにおけるアンチトロンビン III (AT) 製剤の使用方法. Coagulation & Inflammation 2 : 11-17, 2016
4) 木村聡, 平井久也, 内田季之ほか : DIC初発羊水塞栓症と心肺虚脱初発羊水塞栓症の血清マーカーの比較 : 羊水塞栓症登録事業. 日本産婦人科・新生児血液学会誌 20 : S55-56, 2010
5) 日本産科婦人科学会, 日本産婦人科医会, 日本周産期・新生児医学会ほか : 産科危機的出血への対応指針 2017. http://www.jsog.or.jp/activity/pdf/shusanki_shishin2017.pdf
6) 板倉敦夫 : クリオプレシピテートとフィブリノゲン製剤. Thromb Med 2 : 335-341, 2012
7) クリオプレシピテートの院内調製基準作成タスフォース委員会 : クリオプレシピテート作成プロトコール (案). 日本輸血・細胞治療学会. 2016年8月30日
9) Kobayashi T, Nakabayashi M, Yoshioka A et al : Recombinant activated factor VII (rFVIIa/NovoSevenR) in the management of severe postpartum haemorrhage : initial report of a multicentre case series in Japan. Int J Hematol 95 : 57-63, 2012
10) 小林隆夫 : 第VII因子 (遺伝子組換え活性型血液凝固第VII因子製剤) 療法. 臨床婦人科産科 70 : 302-307, 2016
11) Murakami M, Kobayashi T, Kubo T et al : Experience with recombinant activated factor VII for severe post-partum hemorrhage in Japan, investigated by Perinatology Committee, Japan Society of Obstetrics and Gynecology. J Obstet Gynaecol Res 41 : 1161-1168, 2015
12) Makino S, Takeda S, Kobayashi T et al. National survey of fibrinogen concentrate usage for post-partum hemorrhage in Japan : investigated by the Perinatology Committee, Japan Society of Obstetrics and Gynecology. J Obstet Gynaecol Res 41 : 1155-1160, 2015 2009
13) 真木正博, 寺尾俊彦, 池ノ上克 : 産科DICスコア. 産婦人科治療 50 : 119-124, 1985
P.172 掲載の参考文献
4) Di Nisio M, Baudo F, Cosmi B et al : on behalf of the Italian Society for Thrombosis and Haemostasis. Diagnosis and treatment of disseminated intravascular coagulation : Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res 129 : e177-e184, 2012
5) Wada H, Thachil J, Di Nisio M et al : The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis : Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 11 : 761-767, 2013
6) 西田修, 小倉裕司, 井上茂亮ほか : 日本版敗血症診療ガイドライン 2016. 日救急医会誌 28 : S 5-S 12, 2017
7) Guyatt GH, Oxman AD, Vist GE et al : GRADE Working Group. GRADE : an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336 : 924-926, 2008
8) Geerts WH, Pineo GF, Heit JA et al : Prevention of Venous Thromboembolism : The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 : S338-S400, 2004
Chapter 5 トピックス
P.185 掲載の参考文献
3) Engelmann B, Massberg S : Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 13 : 34-45, 2013
4) Clark SR, Ma AC, Tavener SA et al : Platelet TLR 4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 13 : 463-469, 2007
10) Abeyama K, Stern DM, Ito Y et al : The N-terminal domain of thrombomodulin sequesters high-mobility group-B 1 protein, a novel antiinflammatory mechanism. J Clin Invest 115 : 1267-1274, 2005
12) Shi CS, Shi GY, Hsiao SM et al : Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood 112 : 3661-3670, 2008
P.195 掲載の参考文献
2) Braet F, Wisse E : Structural and functional aspects of liver sinusoidal endothelial cell fenestrae : a review. Comp Hepatol 1 : 1-17, 2002
4) Carreras E, Bertz H, Arcese W et al : Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation : a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 92 : 3599-3604, 1998
6) McDonald GB, Hinds MS, Fisher LD et al : Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation : a cohort study of 355 patients. Ann Intern Med 118 : 255-267, 1993
7) Jones RJ, Lee KS, Beschorner WE et al : Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 44 : 778-783, 1987
8) Mohty M, Malard F, Abecassis M, et al : Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients : a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 51 : 906-912, 2016
9) Carreras E : Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol 64 : 281-291, 2000
10) Carreras E, Diaz-Ricart M : The role of the endothelium in the shortterm complications of hematopoietic SCT. Bone Marrow Transplant 46 : 1495-1502, 2011
P.209 掲載の参考文献
P.217 掲載の参考文献
4) 久志本成樹 : プロカルシトニンは何をし, その上昇の意味するものは? 日集中医誌 18 : 330-333, 2011
7) Bouadma L, Luyt CE, Tubach F et al : Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial) : a multicentre randomised controlled trial. Lancet 375 : 463-474, 2010
P.231 掲載の参考文献
1) Fujimura Y, Titani K : Structure and function of von Willebrand factor. Haemostasis and Thrombosis. In : de Bloom AL editor. London : Churchill Livingstone ; 1994.p. 379-395
6) Moschcowitz E : Hyaline thrombosis of terminal arterioles and capillaries : a hitherto undescribed disease. Proc N Y Pathol Soc 24 : 21-24, 1924
8) Moake JL, Rudy CK, Troll JH et al : Unusually large plasma factor VIII : von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 307 : 1432-1435, 1982
9) Asada Y, Sumiyoshi A, Hayashi T et al : Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res 38 : 469-479, 1985
10) Rock GA, Shumak KH, Buskard NA et al : Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325 : 393-397, 1991
11) Furlan M, Robles, Lammle B : Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87 : 4223-4234, 1996
12) Kokame K, Nobe Y, Kokubo Y et al : FRETS-VWF 73, a first fluologenic sunbstrate for ADAMTS 13 assay. Br J Haematol 129 : 93-100, 2005
13) Kato S, Matsumoto M, Matsuyama T et al : Novel monoclonal antibody-based enzyme iimmunoassay for determining plasma levels of ADAMTS 13 activity. Transfusion 46 : 1444-1452, 2006
14) Fujimura Y, Kokame K, Yagi H et al : Hereditary deficiency of ADAMTS 13 activity : Upshaw-Schulman syndrome. ADAMTS 13 Biology and Disease. In de : Rodgers GM editor. Berlin : Springer ; 2015. p. 73-90
15) Schulman I, Pierce M, Lukens A et al : Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production ; chronic thrombocytopenia due to its deficiency. Blood 16 : 943-957, 1960
17) Furlan M, Robles R, Solenthaler M et al : Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 89 : 3097-3103, 1997
18) Kinoshita S, Yoshioka A, Park YD et al : Upshaw-Schulman syndrome revisited : a concept of congenital thrombotic thrombocytopenic purpura. Int J Hematol 74 : 101-108, 2001
19) Levy GG, Nichols JL, Lian EC et al : Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413 : 488-494, 2001
20) Tanabe S, Yagi H, Kimura T, et al : Two newborn-onset patients of Upshaw-Schulman syndrome with distinct subsequent clinical courses. Int J Hematol 96 : 789-797, 2012
21) Fujimura Y, Lammle B, Tanabe S et al : Severe hemolytic jaundice with thrombocytopenia at birth in congenital TTP is caused by physiological constriction of ductus arteriosus. ISTH 2019 (abs)
22) Yoshida Y, Matsumoto M, Yagi H et al : Severe reduction of free-form ADAMTS 13, unbound to von Willebrand factor, in plasma of patients with HELLP syndrome. Blood Adv 1 : 1628-1631, 2017
23) Gill JC, Endres-Brooks J, Bauer PJ et al : The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69 : 1169-1165, 1987
25) Bennett CL, Kim B, Zakarija A et al : Two mechanistic pathways for thienopyridine-associated thrombotic thrombocyteopenic purpura : a report from the SERF-TTP Research Group and the RADAR projects. J Am Coll Cardiol 50 : 1138-1143, 2007
28) Scully M, Hunt BJ, Benjamin S et al : Guidelines on the diagnosis and management of thrombotic thrombocyteopenic purpura and other thrombotic microangiopathies. Br J Haematol 158 : 323-335, 2012
29) Isonishi A, Bennett CL, Plaimauer B et al : Poor responder to plasma exchange therapy in acquired thrombotic thrombocytopenic purpura is associated with ADAMTS 13 inhibitor boosting : visualization of an ADAMTS 13 inhibitor complex and its proteolytic clearance from plasma. Transfusion 55 : 2321-2330, 2015
31) Scully M, Cataland SR, Peyvandi F et al : Caplacizumab treatment for Acquired Thrombotic Thrombocyteopenic Purpura. N Engl J Med 380 : 335-346, 2019
33) Yoshii Y, Fujimura Y, Bennett CL et al. Implementation of a rapid assay of ADAMTS 13 activity was associated with improved 30-day survival rate in patients with acquired primary thrombotic thrombocytopenic purpura who received platelet transfusions. Transfusion 57 : 2045-2053, 2017
P.247 掲載の参考文献
1) Raghu G, Remy-Jardin M, Myers JL et al : Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 198 : e 44-e 68, 2018
2) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編 : 特発性間質性肺炎診断と治療の手引き 改訂第3版. 東京, 南江堂, 2016
4) 厚生労働科学研究費補助金難治性疾患政策研究事業「びまん性肺疾患に関する調査研究」班特発性肺線維症の治療ガイドライン作成委員会編 : 特発性肺線維症の治療ガイドライン 2017. 東京, 南江堂, 2017
6) Otsuka M, Takahashi H, Shuratori M et al : Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. Thorax 59 : 31-38, 2004
9) 桑野和善, 皆川俊介, 荒屋潤 : 分子病態から見た肺線維症. 日内会誌 98 : 1134-1139, 2009
13) Kubo H, Nakayama K, Yanai M et al : Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 128 : 1475-1482, 2005
15) Yard BA, Chonanopoulos E, Herr D et al : Regulation of endothelin-1 and transforming growth factor-β1 production in cultured proximal tubular cells by alubumin and heparin sulphate glycosaminoglycans. Nephrol Dial Transplant 16 : 1769-1775, 2001
17) 吉村邦彦, 中谷龍王, 中森祥隆ほか : 特発性間質性肺炎の急性増悪に関する臨床的検討ならびに考察. 日胸疾会誌 22 : 1012-1020, 1984
21) Collard HR, Ryerson CJ, Corte TJ et al : Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med 194 : 265-275, 2016
27) 渡辺憲弥, 田島俊児, 田中淳一ほか : 急速に進行する間質性肺炎に対する抗凝固療法併用の有効性についての検討. 日呼吸会誌 49 : 407-412, 2011
29) Uchiba M, Okajima K, Murakami K et al : Recombinant thrombomodulin prevents endotoxin-induced lung injury in rats by inhibiting leukocyte activation. Am J Physiol 271 : L470-L475, 1996
31) Vincent JL, Ramesh MK, Ernest D et al : A randomized, double-blind, placebo-controlled, Phase 2 b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 41 : 2069-2079, 2013
32) 旭化成ファーマ株式会社 : ART-123の海外における第3相臨床試験結果 (速報) について. https://www.asahi-kasei.co.jp/asahi/jp/news/2018/me180802.html
34) 谷口博之, 近藤康博, 木村智樹ほか : 特発性肺線維症の急性増悪に対するリコンビナントトロンボモジュリンの有効性の検討. 厚生労働科学研究費補助金難治性疾患克服研究事業びまん性肺疾患調査研究, 平成24年度研究報告書. 2013, p 265?268
41) Arai T, Kida H, Ogata Y et al : Recombinant thrombomodulin for acute exacerbation in idiopathic interstitial pneumonias. Respirology 2019 Mar 5. doi : 10.1111/resp.13514, 2019 [Epub ahead of print]
42) NIH National Library of Medicine : Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis. ClinicalTrials. gov https://clinicaltrials.gov/ct2/show/NCT02739165
P.269 掲載の参考文献
2) Levi M, de Jonge E, van der Poll T, ten Cate H : Disseminated intravascular coagulation. Thromb Haemost 82 : 695-705, 1999
6) 日本血栓止血学会学術標準化委員会DIC部会 : 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス. 日本血栓止血学会雑誌 20 : 77-113, 2009
7) 朝倉英策 : DICの分類. Thrombosis Medicine 1 : 38-44, 2011
13) 真木正博, 寺尾俊彦, 池ノ上克 : 産科DICスコア. 産婦治療 50 : 119-124, 1985
18) 桜井康良, 内田倫子, 愛波淳子, 三村文昭 : 産科DICに対する各診断基準 (急性期DIC診断基準, 改訂厚生省DIC診断基準, 国際血栓止血学会診断基準) シミュレーションによる比較. 麻酔 58 : 732-738, 2009
20) 和田英夫, 下仮屋雄二 : DICの診断と治療の新展開. Thrombosis Medicine 1 : 32-37, 2011
22) Erez O : Disseminated intravascular coagulation in pregnancy-Clinical phenotypes and diagnostic scores. Thrombosis Res 151 Suppl. 1 : S56-S60, 2017
24) Catanzarite VA, Seinberg SM, Mosley CA et al : Severe preeclampsia with fulminant and extreme elevation of aspartate aminotransferase and actate dehydrogenase levels : high risk for maternal death. Am J Perinatol 12 : 310-313, 1995
25) Haram K, Mortensen JH, Mastrolia SA, Erez O : Disseminated intravascular coagulation in the HELLP syndrome : how much do we really know? J Matern Fetal Neonatal Med 30 : 779-788, 2017
26) Hulstein JJ, van Runnard Heimel PJ, Franx A et al : Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome. J Thromb Haemost 4 : 2569-2575, 2006
27) Koenig M, Roy M, Baccot S et al : Thrombotic microangiopathy with liver, gut, and bone infarction (catastrophic antiphospholipid syndrome) associated with HELLP syndrome. Clinical Rheumatol 24 : 166-168, 2005
28) Hoayek JG, Moussa HN, Rehman HA et al : Catastrophic antiphospholipid syndrome in pregnancy, a diagnosis that should not be missed. J Matern Fetal Neonatal Med 29 : 3950-3955, 2016
29) Wada H, Thachi J, Di Nisio M et al : Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013 Feb 4. doi : 10.1111/jth.12155. [Epub ahead of print]
30) Sakuragawa N, Hasegawa H, Maki M et al : Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC) --a multicenter co-operative double-blind trial in comparison with heparin. Thromb Res 72 : 475-500, 1993
32) 鈴木宏治, 武谷浩之 : 凝固線溶系-凝固系の最近の進歩-. Thrombosis Medicine 1 : 13-20, 2011
38) 中本收, 田坂玲子, 本久智賀 : 遺伝子組換えトロンボモジュリン (rTM) 注射薬によって妊娠高血圧腎症重症の分娩後HELLP症候群病態の軽快に寄与できた5症例. 日産婦誌 64 : 528, 2012
39) Marti-Carvajal AJ, Comunian-Carrasco G, Pena-Marti GE : Haematological interventions for treating disseminated intravascular coagulation during pregnancy and postpartum. Cochrane Database Syst Rev 3 : CD 008577, 2011 doi : 10. 1002/ 14651858.CD008577.pub 2.
41) Roberge S, Demers S, Nicolaides KH et al : Prevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin : a meta-analysis. Ultrasound Obstet Gynecol 47 : 548-553, 2016
45) Lindqvist P, Dahlback B, Marsal K : Thrombotic risk during pregnancy : a population study. Obstet Gynecol 94 : 595-599, 1999
46) Paidas MJ, Ku DW, Arkel YS : Screening and management of inherited thrombophilias in the setting of adverse pregnancy outcome. Clin Perinatol 31 : 783-805, 2004
47) Mello G, Parretti E, Fatini C et al : Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-coverting enzyme DD women. Hypertension 5 : 86-91, 2005
48) Horlocker TT, Wedel DJ, Benzon H et al : Regional anesthesia in the anticoagulated patient : defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 28 : 172-197, 2003
49) James A : Practice bulletin no. 123 : thromboembolism in pregnancy. Obstet Gynecol 118 : 718-729, 2011
P.282 掲載の参考文献
1) Miyakis S, Lockshin MD, Atsumi T et al : International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 : 295-306, 2006
2) Atsumi T, Ieko M, Bertolaccini ML et al : Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 43 : 1982-1993, 2000
3) Brandt JT, Barna LK, Triplett DA : Laboratory identification of lupus anticoagulants : results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost 74 : 1597-1603, 1995
4) Atsumi T, Amengual O, Yasuda S et al : Antiprothrombin antibodies--are they worth assaying? Thromb Res 114 : 533-538, 2004
5) Yasuda S, Tsutsumi A, Chiba H et al : β2-glycoprotein I deficiency : prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis. Atherosclerosis 152 : 337-346, 2000
6) Bohgaki M, Atsumi T, Yamashita Y et al : The p 38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-β2 Glycoprotein I antibodies. Int Immunol 16 : 1633-1641, 2004
7) Girardi G, Redecha P, Salmon JE : Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nature medicine 10 : 1222-1226, 2004
8) Oku K, Atsumi T, Bohgaki M et al : Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 68 : 1030-1035, 2009
9) Khamashta MA, Cuadrado MJ, Mujic F et al : The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332 : 993-997, 1995
10) Alarcon-Segovia D, Boffa MC, Branch W et al : Prophylaxis of the antiphospholipid syndrome : a consensus report. Lupus 12 : 499-503, 2003
11) 小池隆夫 : 抗リン脂質抗体症候群の治療指針案について. 厚生省特定疾患対策研究事業, 自己免疫疾患の病因・病態解析と新たな治療法に関する研究報告書, 2002, p 135-137
12) Garcia DA, Khamashta MA, Crowther MA : How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome : a casebased review. Blood 110 : 3122-3127, 2007
14) Shapira I, Andrade D, Allen SL et al : Brief report : induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 64 : 2719-2723, 2012
15) Pierangeli SS, Erkan D : Antiphospholipid syndrome treatment beyond anticoagulation : are we there yet? Lupus 19 : 475-485, 2010
17) Erre GL, Pardini S, Faedda R et al : Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome : a case report and a review of literature. Lupus 17 : 50-55, 2008
P.293 掲載の参考文献
1) Horiuchi H, Doman T, Kokame K et al : Acquired von Willebrand Syndrome Associated with Cardiovascular Diseases. J Atherosclero Thombo 26 : 303-314, 2019
2) Tamura T, Horiuchi H, Imai M et al : Unexpectedly High Prevalence of Acquired von Willebrand Syndrome in Patients with Severe Aortic Stenosis as Evaluated with a Novel Large Multimer Index. J Atheroscler Thomb 22 : 1115-1123, 2015
3) 大北裕, 岡田行功, 尾辻豊ほか : 弁膜疾患の非薬物治療に関するガイドライン 2012年改訂版. http://www.j-circ.or.jp/guideline/pdf/JCS2012_ookita_h.pdf
4) 道満剛之, 堀内久徳 : 後天性フォンウィルブランド症候群 朝倉英策編著. 臨床に直結する血栓止血学 改訂2版 東京, 中外医学社, 2018. p. 213-220
5) Tamura T, Horiuchi H, Obayashi Y et al : Acquired von Willebrand syndrome in patients treated with veno-arterial extracorporeal membrane oxygenation. Cardiovasc Interv Ther 2019 doi : 10.1007/s12928-019-00568-y. [Epub ahead of print]
P.303 掲載の参考文献
5) Charriere JM, Pelissie J, Verd C et al : Survey : retrospective survey of monitoring/safety devices and incidents of cardiopulmonary bypass for cardiac surgery in France. J Extra Corpor Technol 39 : 142-157, 2007
6) Myers GJ, Weighell PR, McCloskey BJ et al : A multicenter investigation into the occurrence of high-pressure excursions. J Extra Corpor Technol 35 : 127-132, 2003
14) 八島望 : 体外循環回路閉塞における細胞外DNAの関与とその制御. 炎症と免疫. 27, 2019 (in printing)
21) Rocha Arrieta YC, Rojas M, Vasquez G et al : The Lymphocytes Stimulation Induced DNA Release, a Phenomenon Similar to NETosis. Scand J Immunol 86 : 229-238, 2017
22) Yu X, Tan J, Diamond SL : Hemodynamic force triggers rapid NETosis within sterile thrombotic occlusions. J Thromb Haemost 16 : 316-329, 2018
23) Cairo MS, Allen J, Higgins C et al : Synergistic effect of heparin and chemotactic factor on polymorphonuclear leukocyte aggregation and degranulation. Am J Pathol 113 : 67-74, 1983
24) Lazarowski ER, Santane JA, Behrens NH et al : Aggregation of human neutrophils by heparin. Thromb Res 41 : 437-446, 1986
25) Thomas GM, Carbo C, Curtis BR et al : Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice. Blood 119 : 6335-6343, 2012
26) Yildiz C, Palaniyar N, Otulakowski G et al : Mechanical ventilation induces neutrophil extracellular trap formation. Anesthesiology 122 : 864-875, 2015
27) Scozzi D, Wang X, Liao F et al : Neutrophil extracellular trap fragments stimulate innate immune responses that prevent lung transplant tolerance. Am J Transplant 19 : 1011-1023, 2019
28) Bull BS, Korpman RA, Huse WM et al : Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 69 : 674-684, 1975
29) Wilm J, Philipp A, Muller T et al : Leukocyte Adhesion as an Indicator of Oxygenator Thrombosis During Extracorporeal Membrane Oxygenation Therapy? ASAIO J 64 : 24-30, 2018
P.316 掲載の参考文献
2) Kumar G, Kumar N, Taneja A et al : Nationwide trends of severe sepsis in the 21 st century (2000-2007). Chest 140 : 1223-1231, 2011
3) Abraham E, Reinhart K, Opal S et al : Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis : a randomized controlled trial. JAMA 290 : 238-347, 2003
4) Bernard GR, Vincent JL, Laterre PF et al : Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 : 699-709, 2001
5) Warren BL, Eid A, Singer P et al : Caring for the critically ill patient. High-dose antithrombin III in severe sepsis : a randomized controlled trial. JAMA 286 : 1869-1878, 2001
6) Engelmann B, Massberg S : Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 13 : 34-45, 2013
7) Levi M, de Jonge E, van der Poll T, ten Cate H : Disseminated intravascular coagulation. Thromb Haemost 82 : 695-705, 1999
9) Coughlin SR : Thrombin signalling and protease-activated receptors. Nature 407 : 258-264, 2000
10) Taylor FB Jr, Toh CH, Hoots WK et al : Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86 : 1327-1330, 2001
11) Angus DC, Crowther MA : Unraveling severe sepsis : why did OPTIMIST fail and what's next? JAMA 290 : 256-258, 2003
12) Crowther MA, Marshall JC : Continuing challenges of sepsis research. JAMA 286 : 1894-1896, 2001
13) Rangel-Frausto MS, Pittet D, Costigan M et al : The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273 : 117-123, 1995
15) Gando S, Saitoh D, Ogura H et al : Disseminated intravascular coagulation (DIC) diagnosed based on the Japanese Association for Acute Medicine criteria is a dependent continuum to overt DIC in patients with sepsis. Thromb Res 123 : 715-718, 2009
16) Ogura H, Gando S, Saitoh D et al : Epidemiology of severe sepsis in Japanese intensive care units : a prospective multicenter study. J Infect Chemother 20 : 157-162, 2014
17) Clark SR, Ma AC, Tavener SA et al : Platelet TLR 4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 13 : 463-469, 2007
18) Ma AC, Kubes P : Platelets, neutrophils, and neutrophil extracellular traps (NETs) in sepsis. J Thromb Haemost 6 : 415-420, 2008
19) Nathan C : Neutrophils and immunity : challenges and opportunities. Nat Rev Immunol 6 : 173-182, 2006
20) Urban C, Zychlinsky A : Netting bacteria in sepsis. Nat Med 13 : 403-404, 2007
21) Semple JW, Italiano JE Jr, Freedman J : Platelets and the immune continuum. Nat Rev Immunol 11 : 264-274, 2011
23) Lee WL, Grinstein S : Immunology. The tangled webs that neutrophils weave. Science 303 : 1477-1478, 2004
24) Brinkmann V, Zychlinsky A : Beneficial suicide : why neutrophils die to make NETs. Nat Rev Microbiol 5 : 577-582, 2007
25) Fuchs TA, Brill A, Duerschmied D et al : Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 107 : 15880-15885, 2010
27) Sun H : The interaction between pathogens and the host coagulation system. Physiology (Bethesda) 21 : 281-288, 2006
28) Umemura Y, Yamakawa K : Efficacy and safety of anticoagulant therapy in three specific populations with sepsis : a meta-analysis of randomized controlled trials : reply. J Thromb Haemost 14 : 2310-2311, 2016
29) Afshari A, Wetterslev J, Brok J, Moller A : Antithrombin III in critically ill patients : systematic review with meta-analysis and trial sequential analysis. BMJ 335 : 1248-1251, 2007
30) Allingstrup M, Wetterslev J, Ravn FB et al : Antithrombin III for critically ill patients : a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 42 : 505-520, 2016
31) Wiedermann CJ. Antithrombin concentrate use in disseminated intravascular coagulation of sepsis : meta-analyses revisited. J Thromb Haemost 16 : 455-457, 2018
32) Wiedermann CJ, Kaneider NC : A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. Blood Coagul Fibrinolysis 17 : 521-526, 2006
33) 日本版敗血症診療ガイドライン2016作成特別委員会 : 日本版敗血症診療ガイドライン 2016. http://www.jaam.jp/html/info/2017/pdf/J-SSCG2016_honpen.pdf
34) Yamakawa K, Aihara M, Ogura H et al : Recombinant human soluble thrombomodulin in severe sepsis : a systematic review and meta-analysis. J Thromb Haemost 13 : 508-519, 2015
35) Zhang C, Wang H, Yang H, Tong Z : Recombinant human soluble thrombomodulin and short-term mortality of infection patients with DIC : a meta-analysis. Am J Emerg Med 34 : 1876-1882, 2016
36) Asahi Kasei Pharma Corp.Preliminary results of overseas Phase III clinical study for ART-123 : https://www.asahi-kasei.co.jp/asahi/en/news/2018/e180802.html
37) Clinical Trials. gov. https://clinicaltrials.gov/ct2/show/NCT03517501
P.327 掲載の参考文献
1) 西田修, 小倉裕司, 井上茂亮ほか : 日本版敗血症診療ガイドライン 2016. http://www.jaam.jp/html/info/2016/pdf/J-SSCG2016_ver2.pdf
2) World Sepsis Day. https://www.world-sepsis-day.org/
11) 日本血栓止血学会学術標準化委員会DIC部会 : 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス. 血栓止血誌 20 : 77-113, 2009
14) Vincent JL, Ramesh MK, Ernest D et al : A randomized, double-blind, placebo-controlled, Phase 2 b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 41 : 2069-2079, 2013
P.335 掲載の参考文献
1) DIC診断基準作成委員会 : http://www.jsth.org/guideline/dic診断基準2017年度版/
2) 日本救急医学会DIC委員会 : 急性期DIC診断基準-5. Dダイマー/FDP換算表の項の改定-. 日救急医会誌 24 : 114-115, 2013
P.342 掲載の参考文献
2) 山本信一 : 新生児, 小児と血液凝固. 武田純三編集. 麻酔科医・集中治療医に必要な血液凝固, 抗凝固, 線溶系が分かる本. 東京, 真興交易 (株) 医書出版部, 2015 p. 132-138
3) 家子正裕, 小宮山豊, 山崎哲ほか : 凝固検査検体取扱いに関するコンセンサス. 日検血会誌 17 : 149-168, 2016
5) 徳永尚樹 : FDP, Dダイマー, 臨床検査 増刊号 59 : 1116-1120, 2015
6) 徳永尚樹 : PT・APTT・フィブリノゲン. 日検血会誌 29 : 558-563, 2018
7) 林朋恵, 朝倉英策 : DICの病態・診断. 日検血会誌 19 : 344-347, 2008
P.352 掲載の参考文献
1) 新井克明, 荘司範子 : 早期治療と適正使用のための中小病院薬剤師による感染症性DIC診療フローチャート作成の試み. 医薬ジャーナル 53 : 905-911, 2017
2) 丸藤哲, 射場敏明, 江口豊ほか : 急性期DIC診断基準 多施設共同前向き試験結果報告. 日救急医会誌 16 : 188-202, 2005
6) 鈴木秀明, 黒田修一, 大重秀世ほか : トロンボモデュリン アルファ (TM-α) 使用成績調査のサブグループ解析-感染症DIC のTM-α最終投与後の急性期DICスコアと転帰の関連-. 新薬と臨牀 68 : 175-193, 2019.
8) 厚生労働省 : 医療スタッフの協働・連携によるチーム医療の推進について. 厚生労働省医政局長通知 (医政発0430 第1号). 2010
9) 一般社団法人日本病院薬剤師会. プロトコールに基づく薬物治療管理 (PBPM) の円滑な進め方と具体的実践事例 (Ver.1.0). 2016. http://www.jshp.or.jp/cont/16/0331-1.pdf
Chapter 6 Question & Answer
P.361 掲載の参考文献
1) 江口豊 : 敗血症の予後改善のために-DICの治療戦略. 血液フロンティア 21 : 1024-1035, 2011
2) Warren BL, Eid A, Singer P et al : Caring for the critically ill patient. High-dose antithrombin III in severe sepsis : a randomized controlled trial. JAMA 286 : 1869-1878, 2001
3) Kienast J, Juers M, Wiedermann CJ et al : Treatment effects of highdose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thrombo Haemost 4 : 90-97, 2006
4) 日本血栓止血学会学術標準化委員会DIC部会ガイドライン作成委員会 : 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサスの追補. 日本血栓止血学会 25 : 123-125, 2014
5) Ito T, Kawahara K, Okamoto K et al : Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thrombo Vasc Biol 28 : 1825-1830, 2008
7) 川杉和夫 : 急性骨髄性白血病に合併したDICに対するrTM製剤の効果. 血液・腫瘍科 60 : 526-531, 2010
P.370 掲載の参考文献
1) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference : definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20 : 864-874, 1992
3) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference : definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20 : 864-874, 1992
4) Marshall JC : SIRS and MODS : what is their relevance to the science and practice of intensive care? Shock 14 : 586-589, 2000
5) Vincent JL : Dear SIRS, I'm sorry to say that I don't like you …. Crit Care Med 25 : 372-374, 1997
6) Levy MM, Fink MP, Marshall JC et al : SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31 : 1250-1256, 2003
8) Vincent JL, Opal SM, Marshall JC et al : Sepsis definitions : time for change. Lancet 381 : 774-775, 2013
9) Singer M, Deutschman CS, Seymour CW et al :The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315 : 801-810, 2016
10) Vincent JL, Moreno R, Takala J et al : The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22 : 707-710, 1996
12) Bernard GR, Artigas A, Brigham KL et al : The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149 : 818-824, 1994
13) 小関一英, 遠藤重厚, 丸藤哲ほか : 急性期DIC診断基準の考え方. 救急医学 30 : 115-119, 2006
P.378 掲載の参考文献
1) Gando S, Iba T, Eguchi Y et al : A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients : Comparing current criteria. Crit Care Med 34 : 625-631, 2006
4) Warren BL, Eid A, Singer P et al : Caring for the critically ill patient. High-dose antithrombin III in severe sepsis : a randomized controlled trial. JAMA 286 : 1869-1878, 2001
6) Bernard GR, Vincent JL, Laterre PF et al : Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 : 699-709, 2001
7) Abraham E, Laterre PF, Garg R et al : Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353 : 1332-1341, 2005
9) Vincent JL, Ramesh MK, Ernest D et al : A randomized, double-blind, placebo-controlled, Phase 2 b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART- 123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 41 : 2069-2079, 2013
11) Asahi Kasei Pharma Corporation : Preliminary results of overseas Phase III clinical study for ART- 123. https://www.asahi-kasei.co.jp/asahi/en/news/2018/e180802.html.
12) Umemura Y, Yamakawa K, Ogura H et al : Efficacy and safety of anticoagulant therapy in three specific populations with sepsis : a meta-analysis of randomized controlled trials. J Thromb Haemost 14 : 518-530, 2016
13) Jameson JL, Longo DL. Precision medicine--personalized, problematic, and promising. N Engl J Med 372 : 2229-2234, 2015
14) Yamakawa K, Umemura Y, Hayakawa M et al : Benefit profile of anticoagulant therapy in sepsis : a nationwide multicentre registry in Japan. Crit Care 20 : 229, 2016
15) Umemura Y, Yamakawa K : Optimal patient selection for anticoagulant therapy in sepsis : an evidence-based proposal from Japan. J Thromb Haemost 16 : 462-464, 2018
16) Umemura Y, Yamakawa K, Hayakawa M et al : Concomitant Versus Individual Administration of Antithrombin and Thrombomodulin for Sepsis-Induced Disseminated Intravascular Coagulation : A Nationwide Japanese Registry Study. Clin Appl Thromb Hemost 24 : 734-740, 2018
P.385 掲載の参考文献
1) DeLeve LD, Shulman HM, McDonald GB : Toxic injury to hepatic sinusoids : sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 22 : 27-42, 2002
2) McDonald GB, Hinds MS, Fisher LD et al : Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation : a cohort study of 355 patients. Ann Intern Med 118 : 255-267, 1993
3) Jones RJ, Lee KS, Beschorner WE et al : Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 44 : 778-783, 1987
4) Mohty M, Malard F, Abecassis M et al : Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients : a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 51 : 906-12, 2016
6) Hashiguchi M, Okamura T, Yoshimoto K et al : Demonstration of reversed flow in segmental branches of the portal vein with hand-held color Doppler ultrasonography after hematopoietic stem cell transplantation. Bone Marrow Transplant 36 : 1071-1075, 2005
10) Yakushijin K, Okamura A, Ono K et al : Defibrotide therapy for patients with sinusoidal obstruction syndrome after hematopoietic stem cell transplantation. Rinsho Ketsueki 50 : 3-8, 2009
11) Palmer KJ, Goa KL : Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs 45 : 259-294, 1993
13) Richardson PG, Riches ML, Kernan NA et al : Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood 127 : 1656-1665, 2016
18) Nomura S, Ishii K, Inami N et al : Evaluation of angiopoietins and cellderived microparticles after stem cell transplantation. Biol Blood Marrow Transplant 14 : 766-774, 2008
19) Tsubokura M, Yamashita T, Inagaki L et al : Fatal intracranial hemorrhage following administration of recombinant thrombomodulin in a patient after cord blood transplantation. Bone Marrow Transplant 46 : 1030-1031, 2011
22) de Fontbrune FS, Galambrun C, Sirvent A et al : Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy : A Study From the SFGM-TC. Transplantation 99 : 1953-1959, 2015
P.399 掲載の参考文献
1) Montgomery RR, Scott JP : Disseminated intravascular coagulation (Consumptive coagulopathy) (Behrman RE, Kliegman RM, Jenson HB eds). WB Saunders Company, St Louis, 1999, p 1519-1520
2) Warren BL, Eid A, Singer P et al : High-dose antithrombin III in severe sepsis : A randomized controlled trial. JAMA 286 : 1869-1878, 2001
4) Scott JP, Montgomery RR : Hematologic and thrombotic disease (Kliegman RM eds). WB Sanuders Company, St Louis, 2007, p 2060-2089
5) 白幡聡, 高橋幸博, 茨聡ほか : 新生児DIC診断・治療指針 2016年版. 日産婦新生児血会誌 25 : 3-34, 2016
7) 中村外士雄, 有吉宣明, 朝倉昭雄ほか : 小児のDICに対するメシル酸ガベキサートの投与効果. 日小血会誌 1 : 75-83, 1987
8) 塙坂八重, 高橋幸博, 川口千晴ほか : 新生児の播種性血管内凝固に対するメシル酸ナファモスタット (Futhan) の治療効果-メシル酸ガベキサート (FOY) との比較-. 日小血会誌 18 : 23-28, 2004
9) 白幡聡, 白川嘉継, 吉田雄司ほか : 新生児のDICに対するアンチトロンビン III 濃縮製剤の有用性. 新生児誌 29 : 98-105, 1993
11) Shirahata A, Takahashi H, Kitajima I et al : Recombinant soluble human thrombomodulin (thrombomodulin α) in the treatment of neonatal disseminated intravascular coagulation. Eur J Pediatr 173 : 303-311, 2014
12) Shirahata A, Mimuro J, Takahashi H et al : Post-marketing surveillance of recombinant human soluble thrombomodulin (thrombomodulin α) in pediatric patients with disseminated intravascular coagulation. Clin Appl Thromb/Hemost (in press)
P.405 掲載の参考文献
2) 丸山征郎, 坂田洋一, 和田英夫ほか : 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス. 日本血栓止血学会誌 20 : 77-113, 2009
3) Rangel-Frausto MS, Pittet D, Costigan M et al : The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273 : 117-123, 1995
5) 内藤澄悦, 家子正裕, 吉田美香ほか : ヘパリン治療のモニタリングにおける種々のAPTT試薬およびヘパリン投与量の相関性に関する検討. 日検血会誌 13 : 160-166, 2012
P.414 掲載の参考文献
16) Xiao W, Mindrinos MN, Seok J et al : A genomic storm in critically injured humans. J Exp Med 208 : 2581-2590, 2011
P.425 掲載の参考文献
1) 日本救急医学会熱中症に関する委員会 : 熱中症の実態調査-日本救急医学会 Heatstroke STUDY 2012 最終報告-. 日救急医会誌. 25 : 846-862, 2014
2) 日本救急医学会 : 熱中症診療ガイドライン 2015. https://www.mhlw.go.jp/file/06-Seisakujouhou-10800000-Iseikyoku/heatstroke2015.pdf
10) 櫻井聖大, 山田周, 北田真己ほか : III度熱中症に伴うDICに対してトロンボモデュリンアルファが奏効した2症例. 日救急医会誌 24 : 367-373, 2013
最近チェックした商品履歴
Loading...